IEEE Pulse · Jun 2026
Explains how SafeBeat’s beat-by-beat ECG AI supports transparent QTc measurement and clinician-directed cardiac therapy, with a focus on AF treatment workflows.
Guiding cardiac therapeutics - all from your phone
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Physician-led digital health company building explainable AI ECG software that turns FDA-cleared wearable data into remote therapeutic monitoring and treatment guidance for atrial fibrillation; the product is still under development and limited to investigational use only.
Primary product
Explainable AI ECG software for remote therapeutic monitoring and QTc / antiarrhythmic drug management
Founded
2020
Headquarters
Saint Louis, Missouri, United States
Team size
11-50
Work style
Flexible
Industry
Digital Health
Sub-industry
AI cardiac monitoring / remote therapeutic monitoring
Offices
4455 Duncan Ave Ste 8N, Saint Louis, Missouri 63110, United States
San Francisco, California, United States
Business model
B2B SaaS
Enterprise software licensing
Clinical and research partnerships
Funding
Stage
Seed / pre-Series A
Total raised
$2.4M
Latest round
Direct-to-Phase II SBIR grant · Aug 2025
Latest amount
$2M
Aug 2025 · NIH / NHLBI
Sep 2024 · NIH / NHLBI
Aug 2021 · Zillionize
Phase II SBIR supplement award
NIH / NHLBI
People & investors
Leadership
Rachita Navara, MD, FACC, FHRS
Founder & CEO
President, Founder & CTO
Walker McHugh
Chief of Staff & Head of Research
Vinko Buble
Head of Engineering
Head of Backend Engineering
Manager, Regulatory Affairs
Margaret Ferrari, PhD
Director, Research & Clinical Operations
Technical Advisor
Machine Learning Engineer and Full Stack Developer
Associate Director of Research
Work & culture
Mission-driven, physician-led, research-heavy startup culture focused on engineering for cardiac care, explainable AI, clinical validation, and fast startup execution.
Work style
Flexible
Compensation
Public salary ranges in YC job postings include Head of Growth at $100K-$120K and Sales Development Representative at $50K-$95K. One posted role requires U.S. work authorization without sponsorship. Other roles do not disclose pay.
Product & market
Pricing
Enterprise contracts / B2B software licensing, with reimbursement-aligned clinical workflow software
Differentiators
- —Beat-by-beat, explainable ECG AI rather than opaque global interval estimates
- —Designed to guide treatment decisions, not just diagnose arrhythmia
- —Uses third-party FDA-cleared cardiac devices and mobile workflows
- —Clinician-directed monitoring with digital calipers and adjustable QTc review
- —Built for remote therapeutic monitoring of atrial fibrillation medication workflows
Technology
Python
React
PostgreSQL
Terraform
PyTorch
TypeScript
Keras
Django
MLOps
Salesforce
HubSpot
Pipedrive
Segment
explainable AI
machine learning
API integrations
Customers
Atrial fibrillation patients
Cardiologists and electrophysiologists
Enterprise cardiology networks
Clinicians using FDA-cleared wearable cardiac monitors
UCSF clinical research partners
Competitors
CitiusTech
Lantern
Knownwell
Scale & contact
Estimated revenue
US$3.9M estimated ARR (Apr 2025); other third-party estimators also place it as high as US$5M-$10M
Latest news
SafeBeat Rx LinkedIn · Apr 2026
Company said it was presenting three studies at HRS2026 and positioning its ECG AI as a treatment-guidance tool beyond diagnostics.
SafeBeat Rx LinkedIn · Mar 2026
Announced four research abstracts covering adverse-event patterns in sotalol/dofetilide, QTc prediction, ICM-derived QTc monitoring, and EMR medication-data extraction.
SafeBeat Rx · Aug 2025
Official announcement of a Direct-to-Phase II SBIR grant of about $2M from NIH/NHLBI to validate the company’s mobile ECG analysis software at UCSF.
SafeBeat Rx · Jan 2025
Summarizes three 2025 abstracts on AF remote monitoring, educational analysis, and automated QTc measurements; also reiterates backing from Y Combinator, 50 Years, and Fusion Fund.
Jobs and careers at SafeBeat
0 jobs at SafeBeat
No open positions
Check back later for new openings